Request Demo
Last update 28 Jan 2026
Amprenavir/ritonavir
Last update 28 Jan 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2/3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC37H48N6O5S2 |
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N |
CAS Registry155213-67-5 |
View All Structures (2)
Related
2
Clinical Trials associated with Amprenavir/ritonavirNCT00038519
An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.
NCT00038532
An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
100 Clinical Results associated with Amprenavir/ritonavir
Login to view more data
100 Translational Medicine associated with Amprenavir/ritonavir
Login to view more data
100 Patents (Medical) associated with Amprenavir/ritonavir
Login to view more data
100 Deals associated with Amprenavir/ritonavir
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HIV Infections | Phase 3 | United States | 01 Apr 2001 | |
| HIV Infections | Phase 3 | Argentina | 01 Apr 2001 | |
| HIV Infections | Phase 3 | Brazil | 01 Apr 2001 | |
| HIV Infections | Phase 3 | Canada | 01 Apr 2001 | |
| HIV Infections | Phase 3 | France | 01 Apr 2001 | |
| HIV Infections | Phase 3 | Italy | 01 Apr 2001 | |
| HIV Infections | Phase 3 | Poland | 01 Apr 2001 | |
| HIV Infections | Phase 3 | Spain | 01 Apr 2001 | |
| HIV Infections | Phase 3 | United Kingdom | 01 Apr 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | 291 | cocvpgwimv(wuinfjdfmt) = ABC hypersensitivity was reported in 6% of subjects qthfkzgixd (eqrlchszjf ) | - | 01 Jan 2002 | ||
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free